{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:37:28Z","timestamp":1787258248512,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,18]],"date-time":"2014-12-18T00:00:00Z","timestamp":1418860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.vaccine.2014.12.024","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T15:47:10Z","timestamp":1419954430000},"page":"789-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u226550 years: A randomised non-inferiority clinical trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Javier","family":"Diez-Domingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garcia de Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudius U.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Eymin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sadorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.12.024_bib0005","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1369-5274(00)00233-2","article-title":"Varicella-zoster virus: molecular virology and virus\u2013host interactions","volume":"4","author":"Arvin","year":"2001","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1017\/S0950268808000678","article-title":"Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom","volume":"137","author":"Gauthier","year":"2009","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0015","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/0002512-200825120-00002","article-title":"Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient","volume":"25","author":"Johnson","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0025","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1016\/j.vaccine.2007.07.036","article-title":"The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region","volume":"25","author":"Nardone","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0030","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1086\/521365","article-title":"Varicella-zoster-virus genotypes in East London: a prospective study in patients with herpes zoster","volume":"196","author":"Sengupta","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0035","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2334-13-170","article-title":"Similar herpes zoster incidence across Europe: results from a systematic literature review","volume":"13","author":"Pinchinat","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0950268801005921","article-title":"Epidemiology of varicella zoster virus infection in Canada and the United Kingdom","volume":"127","author":"Brisson","year":"2001","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0045","first-page":"9","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/320169","article-title":"Herpes zoster in older adults","volume":"32","author":"Schmader","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jcgg.2013.03.001","article-title":"Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future","volume":"4","author":"Mick","year":"2013","journal-title":"J Clin Gerontol Geriat"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0060","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMcp1403062","article-title":"Clinical practice. Postherpetic neuralgia","volume":"371","author":"Johnson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0065","series-title":"Pain research and clinical management","first-page":"39","article-title":"The epidemiology and natural history of herpes zoster and postherpectic neuralgia","author":"Dworkin","year":"2001"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0070","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1586\/14737175.7.11.1581","article-title":"Postherpetic neuralgia: epidemiology, pathophysiology and management","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Rev Neurother"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.12.024_bib0075","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/jmv.10316","article-title":"A study of shingles and the development of postherpetic neuralgia in East London","volume":"70","author":"Scott","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0080","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.4065\/82.11.1341","article-title":"A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction","volume":"82","author":"Yawn","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coviro.2011.07.007","article-title":"Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer","volume":"1","author":"Frazer","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0090","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/infdis\/jit342","article-title":"Varicella-zoster virus-specific antibody responses in 50\u201359-year-old recipients of zoster vaccine","volume":"208","author":"Levin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0100","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1056\/NEJMp058091","article-title":"Aging, immunity, and the varicella-zoster virus","volume":"352","author":"Arvin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0105","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2567.2007.02555.x","article-title":"Immunosenescence: emerging challenges for an ageing population","volume":"120","author":"Aw","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/IAI.32.1.24-27.1981","article-title":"Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged","volume":"32","author":"Berger","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF00916011","article-title":"Lymphocyte responses to varicella zoster virus in the elderly","volume":"7","author":"Hayward","year":"1987","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1212\/WNL.30.6.582","article-title":"Selective decline in cellular immune response to varicella-zoster in the elderly","volume":"30","author":"Miller","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0125","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0130","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.pain.2011.10.026","article-title":"Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over 50 years in general practice","volume":"153","author":"Bouhassira","year":"2012","journal-title":"Pain"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0135","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1503\/cmaj.091711","article-title":"The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study","volume":"182","author":"Drolet","year":"2010","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1473-3099(02)00437-1","article-title":"Ageing and infection","volume":"2","author":"Gavazzi","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1741-7015-8-37","article-title":"The impact of herpes zoster and post-herpetic neuralgia on quality-of-life","volume":"8","author":"Johnson","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1533-2500.2010.00432.x","article-title":"Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly","volume":"11","author":"Pickering","year":"2011","journal-title":"Pain Pract"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/AJP.0b013e318065b6c9","article-title":"The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults","volume":"23","author":"Schmader","year":"2007","journal-title":"Clin J Pain"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0160","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10389-010-0323-0","article-title":"Impact of herpes zoster and post-herpetic neuralgia on patients\u2019 quality of life: a patient-reported outcomes survey","volume":"18","author":"Weinke","year":"2010","journal-title":"Z Gesundh Wiss"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0165","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.coi.2012.06.002","article-title":"Immune senescence and vaccines to prevent herpes zoster in older persons","volume":"24","author":"Levin","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0170","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/CVI.00310-07","article-title":"A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax","volume":"15","author":"Gilderman","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.12.024_bib0175","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1086\/514264","article-title":"Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect","volume":"178","author":"Levin","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/infdis\/166.2.253","article-title":"Immune response of elderly individuals to a live attenuated varicella vaccine","volume":"166","author":"Levin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0185","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/379048","article-title":"Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine","volume":"188","author":"Levin","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0190","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/WNL.45.12_Suppl_8.S41","article-title":"Immunization to reduce the frequency and severity of herpes zoster and its complications","volume":"45","author":"Oxman","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0195","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0264-410X(99)00510-1","article-title":"Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose\u2013response trial","volume":"18","author":"Trannoy","year":"2000","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.12.024_bib0200","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1086\/522159","article-title":"Vaccination against herpes zoster and postherpetic neuralgia","volume":"197","author":"Oxman","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0205","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0210","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1532-5415.2010.03021.x","article-title":"Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults","volume":"58","author":"Schmader","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0215","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0220","series-title":"ZOSTAVAX SmPC","author":"EMA","year":"2014"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0225","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.4161\/hv.7.10.16480","article-title":"Immunogenicity and safety of ZOSTAVAX\u00ae approaching expiry potency in individuals aged \u226550 years","volume":"7","author":"Arnou","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0230","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1532-5415.2007.01397.x","article-title":"Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older","volume":"55","author":"Kerzner","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0264-410X(96)00107-7","article-title":"Comparison of gpELISA and neutralizing antibody responses to Oka\/Merck live varicella vaccine (Varivax) in children and adults","volume":"15","author":"Krah","year":"1997","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2014.12.024_bib0240","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/jmv.10318","article-title":"Measurement of cell-mediated immunity with a Varicella-Zoster Virus-specific interferon-gamma ELISPOT assay: responses in an elderly population receiving a booster immunization","volume":"70","author":"Smith","year":"2003","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0245","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults >\/=60 years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0250","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhya"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0255","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.medmal.2008.09.012","article-title":"Are there differences in immunogenicity and safety of vaccines according to the injection method?","volume":"38","author":"Ajana","year":"2008","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0260","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.2014.883285","article-title":"Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature","volume":"13","author":"Herzog","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0265","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1742-4933-9-15","article-title":"Hallmarks of human \u201cimmunosenescence\u201d: adaptation or dysregulation?","volume":"9","author":"Pawelec","year":"2012","journal-title":"Immun Ageing"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0270","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/529197","article-title":"Biology of immune responses to vaccines in elderly persons","volume":"46","author":"Weinberger","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0275","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/528696","article-title":"Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine","volume":"197","author":"Levin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0280","series-title":"ZOSTAVAX SmPC","author":"EMA","year":"2013"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0285","series-title":"ProQuad SmPC","author":"EMA","year":"2014"},{"key":"10.1016\/j.vaccine.2014.12.024_bib0290","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1741-7015-7-16","article-title":"Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial","volume":"7","author":"Gillet","year":"2009","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T13:21:13Z","timestamp":1598620873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14016673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0264410X14016673"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.12.024","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged \u226550 years: A randomised non-inferiority clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}